(NASDAQ: NERV) Minerva Neurosciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.94%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 36.33%.
Minerva Neurosciences's earnings in 2026 is -$293,423,177.On average, 4 Wall Street analysts forecast NERV's earnings for 2026 to be -$33,325,614, with the lowest NERV earnings forecast at -$36,895,752, and the highest NERV earnings forecast at -$29,080,395. On average, 4 Wall Street analysts forecast NERV's earnings for 2027 to be -$25,159,735, with the lowest NERV earnings forecast at -$27,989,881, and the highest NERV earnings forecast at -$21,810,297.
In 2028, NERV is forecast to generate -$19,642,249 in earnings, with the lowest earnings forecast at -$22,900,811 and the highest earnings forecast at -$15,903,341.